1353 related articles for article (PubMed ID: 33180097)
1. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.
Lenze EJ; Mattar C; Zorumski CF; Stevens A; Schweiger J; Nicol GE; Miller JP; Yang L; Yingling M; Avidan MS; Reiersen AM
JAMA; 2020 Dec; 324(22):2292-2300. PubMed ID: 33180097
[TBL] [Abstract][Full Text] [Related]
2. The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial.
Reiersen AM; Mattar C; Bender Ignacio RA; Boulware DR; Lee TC; Hess R; Lankowski AJ; McDonald EG; Miller JP; Powderly WG; Pullen MF; Rado JT; Rich MW; Schiffer JT; Schweiger J; Spivak AM; Stevens A; Vigod SN; Agarwal P; Yang L; Yingling M; Gettinger TR; Zorumski CF; Lenze EJ
Open Forum Infect Dis; 2023 Aug; 10(8):ofad419. PubMed ID: 37622035
[TBL] [Abstract][Full Text] [Related]
3. Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.
Stewart TG; Rebolledo PA; Mourad A; Lindsell CJ; Boulware DR; McCarthy MW; Thicklin F; Garcia Del Sol IT; Bramante CT; Lenert LA; Lim S; Williamson JC; Cardona OQ; Scott J; Schwasinger-Schmidt T; Ginde AA; Castro M; Jayaweera D; Sulkowski M; Gentile N; McTigue K; Felker GM; DeLong A; Wilder R; Rothman RL; Collins S; Dunsmore SE; Adam SJ; Hanna GJ; Shenkman E; Hernandez AF; Naggie S;
JAMA; 2023 Dec; 330(24):2354-2363. PubMed ID: 37976072
[TBL] [Abstract][Full Text] [Related]
4. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
McCarthy MW; Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Felker GM; Jayaweera D; Sulkowski M; Gentile N; Bramante C; Singh U; Dolor RJ; Ruiz-Unger J; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna G; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
JAMA; 2023 Jan; 329(4):296-305. PubMed ID: 36633838
[TBL] [Abstract][Full Text] [Related]
5. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
7. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.
Reis G; Dos Santos Moreira-Silva EA; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; de Souza Campos VH; Nogueira AMR; de Almeida APFG; Callegari ED; de Figueiredo Neto AD; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Glushchenko AV; Rayner CR; Lenze EJ; Reiersen AM; Guyatt GH; Mills EJ;
Lancet Glob Health; 2022 Jan; 10(1):e42-e51. PubMed ID: 34717820
[TBL] [Abstract][Full Text] [Related]
8. Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial.
Wannigama DL; Hurst C; Phattharapornjaroen P; Hongsing P; Sirichumroonwit N; Chanpiwat K; Rad S M AH; Storer RJ; Ounjai P; Kanthawee P; Ngamwongsatit N; Kupwiwat R; Kupwiwat C; Brimson JM; Devanga Ragupathi NK; Charuluxananan S; Leelahavanichkul A; Kanjanabuch T; Higgins PG; Badavath VN; Amarasiri M; Verhasselt V; Kicic A; Chatsuwan T; Pirzada K; Jalali F; Reiersen AM; Abe S; Ishikawa H;
EClinicalMedicine; 2024 Apr; 70():102517. PubMed ID: 38516100
[TBL] [Abstract][Full Text] [Related]
9. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
10. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Gentile N; Collins S; McCarthy MW; Jayaweera D; Castro M; Sulkowski M; McTigue K; Thicklin F; Felker GM; Ginde AA; Bramante CT; Slandzicki AJ; Gabriel A; Shah NS; Lenert LA; Dunsmore SE; Adam SJ; DeLong A; Hanna G; Remaly A; Wilder R; Wilson S; Shenkman E; Hernandez AF;
JAMA; 2022 Oct; 328(16):1595-1603. PubMed ID: 36269852
[TBL] [Abstract][Full Text] [Related]
11. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
[TBL] [Abstract][Full Text] [Related]
12. Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial.
Seo H; Kim H; Bae S; Park S; Chung H; Sung HS; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Son KY; Chong YP
Infect Chemother; 2022 Mar; 54(1):102-113. PubMed ID: 35384422
[TBL] [Abstract][Full Text] [Related]
13. Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial.
Farahani RH; Ajam A; Naeini AR
BMC Infect Dis; 2023 Mar; 23(1):197. PubMed ID: 37003990
[TBL] [Abstract][Full Text] [Related]
14. Effect of Higher-Dose Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial.
; Naggie S
medRxiv; 2023 Sep; ():. PubMed ID: 37745371
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.
Prasanth MI; Wannigama DL; Reiersen AM; Thitilertdecha P; Prasansuklab A; Tencomnao T; Brimson S; Brimson JM
Sci Rep; 2024 Jun; 14(1):13462. PubMed ID: 38862591
[TBL] [Abstract][Full Text] [Related]
16. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
Bramante CT; Huling JD; Tignanelli CJ; Buse JB; Liebovitz DM; Nicklas JM; Cohen K; Puskarich MA; Belani HK; Proper JL; Siegel LK; Klatt NR; Odde DJ; Luke DG; Anderson B; Karger AB; Ingraham NE; Hartman KM; Rao V; Hagen AA; Patel B; Fenno SL; Avula N; Reddy NV; Erickson SM; Lindberg S; Fricton R; Lee S; Zaman A; Saveraid HG; Tordsen WJ; Pullen MF; Biros M; Sherwood NE; Thompson JL; Boulware DR; Murray TA;
N Engl J Med; 2022 Aug; 387(7):599-610. PubMed ID: 36070710
[TBL] [Abstract][Full Text] [Related]
17. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
[TBL] [Abstract][Full Text] [Related]
18. Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial.
Reis G; Dos Santos Moreira Silva EA; Medeiros Silva DC; Thabane L; de Souza Campos VH; Ferreira TS; Quirino Dos Santos CV; Ribeiro Nogueira AM; Figueiredo Guimaraes Almeida AP; Cançado Monteiro Savassi L; de Figueiredo Neto AD; Bitarães C; Cruz Milagres A; Diniz Callegari E; Campos Simplicio MI; Barra Ribeiro L; Oliveira R; Harari O; Wilson LA; Forrest JI; Ruton H; Sprague S; McKay P; Guo CM; Guyatt GH; Rayner CR; Boulware DR; Ezer N; Lee TC; McDonald EG; Bafadhel M; Butler C; Rodrigues Silva J; Dybul M; Mills EJ;
Ann Intern Med; 2023 May; 176(5):667-675. PubMed ID: 37068273
[TBL] [Abstract][Full Text] [Related]
19. Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial.
McCarthy MW; Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Felker GM; Jayaweera D; Sulkowski M; Gentile N; Bramante C; Singh U; Dolor RJ; Ruiz-Unger J; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna G; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
medRxiv; 2022 Nov; ():. PubMed ID: 36299427
[TBL] [Abstract][Full Text] [Related]
20. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
